LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents

Abstract LILRB4 is expressed in AML M4/M5 cells and negatively regulates immune cell activation via T-cell suppression. Its expression and role in chronic myelomonocytic leukemia (CMML) and myelodysplastic syndrome (MDS) are unknown. We investigated LILRB4 expression in 19 CMML and 27 MDS patients and correlated it with response to subsequent hypomethylating agent (HMA) therapy. LILRB4 RNA expression was increased in CMML patients when compared to MDS patients and healthy controls (q < 0.1) and slightly increased in patients who responded to HMAs (q > 0.1). Pathway analysis revealed upregulation of PD-1 signaling, CTLA-4 signaling, and inflammatory response, and gene correlates were positively associated with CTLA-4 expression. Given current modest results with immunotherapy in myeloid malignancies, further investigation of LILRB4 as an immune checkpoint inhibitor target is needed. With the positive correlation between LILRB4 and CTLA-4 expression, combining anti-LILRB4 and anti-CTLA-4 agents may be a novel therapeutic approach in myeloid malignancies that warrants larger studies.

[1]  A. Goldberg,et al.  Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets , 2019, Current Oncology Reports.

[2]  J. Bewersdorf,et al.  Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era? , 2019, Blood reviews.

[3]  C. Zhang,et al.  A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  Benjamin P. C. Chen,et al.  LILRB4 signaling in leukemia cells mediates T cell suppression and tumor infiltration , 2018, Nature.

[5]  E. Warren,et al.  A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure , 2018, Clinical Cancer Research.

[6]  J. Kline,et al.  Mechanisms of Immune Tolerance in Leukemia and Lymphoma. , 2017, Trends in immunology.

[7]  P. Sharma,et al.  Phase IB/II Study of Nivolumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML) , 2016 .

[8]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[9]  C. Zhang,et al.  Inhibitory leukocyte immunoglobulin-like receptors: Immune checkpoint proteins and tumor sustaining factors , 2015, Cell cycle.

[10]  H. Groen,et al.  Immunoglobulin-like transcript 3 is expressed by myeloid-derived suppressor cells and correlates with survival in patients with non-small cell lung cancer , 2015, Oncoimmunology.

[11]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[12]  Cole Trapnell,et al.  TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions , 2013, Genome Biology.

[13]  V. D’Agati,et al.  Soluble Ig-Like Transcript 3 Inhibits Tumor Allograft Rejection in Humanized SCID Mice and T Cell Responses in Cancer Patients1 , 2007, The Journal of Immunology.

[14]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[15]  S. Kim-Schulze,et al.  Recombinant Ig-Like Transcript 3-Fc Modulates T Cell Responses via Induction of Th Anergy and Differentiation of CD8+ T Suppressor Cells1 , 2006, The Journal of Immunology.

[16]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Manfred Brockhaus,et al.  A Novel Inhibitory Receptor (ILT3) Expressed on Monocytes, Macrophages, and Dendritic Cells Involved in Antigen Processing , 1997, The Journal of experimental medicine.

[18]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[19]  N. Rouas-Freiss,et al.  HLA-G: An Immune Checkpoint Molecule. , 2015, Advances in immunology.

[20]  G. Serban,et al.  Expression of immune inhibitory receptor ILT3 in acute myeloid leukemia with monocytic differentiation , 2013, Cytometry. Part B, Clinical cytometry.